Senescence-related truncation and multimerization of apolipoprotein a-i in high-density lipoprotein with an elevated level of advanced glycated end products and cholesteryl ester transfer activity

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 65 A, Issue 6, 2010, Pages 600-610

  Park, Ki Hoon ^a   Shin, Dong Gu ^b   Kim, Jae Ryong ^a   Cho, Kyung Hyun ^a  

^a Yeungnam University   (South Korea)

^b Yeungnam University Hospital   (South Korea)

Author keywords

Advanced glycated end products; Aging; Apolipoprotein; Cholesteryl ester transfer protein; Lipoprotein

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPROTEIN; LIPID; LIPOPROTEIN; SERUM AMYLOID A; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; AGING; ARTICLE; BLOOD; CHEMISTRY; COMPARATIVE STUDY; HUMAN; ISOLATION AND PURIFICATION; MALE; METABOLISM; PARTICLE SIZE; REFERENCE VALUE;

AGED; AGING; ANTIOXIDANTS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, HDL; MALE; PARTICLE SIZE; PROTEIN ISOFORMS; REFERENCE VALUES; SERUM AMYLOID A PROTEIN; TRIGLYCERIDES; URIC ACID; YOUNG ADULT;

EID: 77952969461     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glq034     Document Type: Article

References (41)

1. Barrett-Connor E, Suarez L, Khaw K, Criqui MH, Wingard DL. Isch-emic heart disease risk factors after age 50. J Chronic Dis. 1984;37: 903-908.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. Am J Med. 1977;62: 707-714.
3. Brewer HB. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2004;24: 387-391.
4. Walldius G, Jungner I. apolipoprotein B and apolipoprotein a-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. 2004;255: 188-205.
5. Boguski MS, Freeman M, Elshourbagy NA, Taylor JM, Gordon JI. on computer-assisted analysis of biological sequences: proline punctuatioN, consensus sequenceS, and apolipoprotein repeats. J Lipid Res. 1986;27: 1011-1034.
6. Feng H, Li Xa. Dysfunctional high-density lipoprotein. Curr Opin Endocrinol Diabetes Obes. 2009;16: 156-162.
7. Ji Y, Jonas A. Properties of an n-terminal proteolytic fragment of apo-lipoprotein aI in solution and in reconstituted high density lipopro-teins. J Biol Chem. 1995;270: 11290-11297.
8. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an in-fammatory enzyme for generating dysfunctional high density lipopro-tein. Curr Opin Cardiol. 2006;21: 322-328.
9. Patsch W, Kuisk I, Glueck C, Schonfeld G. Lipoproteins in familial hyperalphalipoproteinemia. Arteriosclerosis. 1981;1: 156-161.
10. Nikkila M, Heikkinen J. High-density lipoprotein cholesterol and longevity. Age Ageing. 1990;19: 119-124.
11. Khalil A, Jay-Gerin JP, Fulop T. age-related increased susceptibility of high-density lipoproteins (HDL) to in vitro oxidation induced by g-radiolysis of water. FEBS Lett. 1998;435: 153-158.
12. Seres I, Paragh G, Deschene E, Fulop T, Khalil A. Study of factors infuencing the decreased HDL associated Pon1 activity with aging. Exp Gerontol. 2004;39: 59-66.
13. Pongor S, Ulrich PC, Bencsath FA, Creami A. Aging of proteins: isolation and identifcation of a fuorescent chromophore from the reaction of polypeptides with glucose. Proc Natl Acad Sci USA. 1984;81: 2684-2688.
14. Gussekloo J, Schaap MCL, Frolich M, Blauw GJ, Westendorp RGJ. C-reactive protein is a strong but nonspecifc risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol. 2000;20: 1047-1051.
15. Collins AR, Lyon CJ, Xia X, et al. age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res. 2008;104: e42-e54.
16. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34: 1345-1353.
17. Markwell MA, Haas SM, Bieber LL, Tolbert NE. A modifcation of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978;87: 206-210.
18. Blois MS. Antioxidant determinations by the use of a stable free radical. Nature. 1958;181: 1199-1200.
19. McPherson JD, Shilton BH, Walton DJ. role of fructose in glycation and cross-linking of proteins. Biochemistry. 1988;27: 1901-1907.
20. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FraP) as a measure of antioxidant power: the FraP assay. Anal Biochem. 1996;239: 70-76.
21. Esterbauer H, Striegl G, Puhl H, rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 1989;6: 67-75.
22. Eckerson HW, Wyte CM, La Du Bn. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35: 1126-1138.
23. Cho KH, Lee JY, Choi MS, Cho JM, Lim JS, Park YB. a peptide from hog plasma that inhibits human cholesteryl ester transfer protein. Biochim Biophys Acta. 1998;1391: 133-144.
24. Brewer HB, Ronan R, Meng M, Bishop C. Isolation and characterization of apolipoprotein a-I, a-II, and a-IV. Methods Enzymol. 1986;28: 223-246.
25. Cho KH, Park JE, Kim YO, Choi I, Kim JJ, Kim JR. The functioN, compositioN, and particle size of high-density lipoprotein were severely impaired in an oliguric phase of hemorrhagic fever with renal syndrome. Clin Biochem. 2008;41: 56-64.
26. Borownlee M, Cerami A, Vlassara H. advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318: 1315-1321.
27. Bose T, Chakraborti AS. Fructose-induced structural and functional modifcations of hemoglobin: implication for oxidative stress in diabetes mellitus. Biochim Biophys Acta. 2008;1780: 800-808.
28. Cho KH, Shin DG, Baek SH, Kim JR. Myocardial infarction patients showed altered lipoprotein compositions compared with angina pecto-ris patients. Exp Mol Med. 2009;41: 67-76.
29. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999;19: 330-335.
30. Erlich PM, Lunetta KL, Cupples LA, et al. Polymorphisms in the Pon gene cluster are associated with alzheimer disease. Hum Mol Genet. 2006;15: 77-85.
31. Zeller M, Masson D, Farnier M, et al. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction. J Am Coll Cardiol. 2007;50: 1948-1955.
32. Cho KH. Synthesis of reconstituted high-density lipoprotein (rHDL) containing apoa-I and apoC-III: the functional role of apoC-III in rHDL. Mol Cells. 2009;27: 291-297.
33. Panzenböck U, Kritharides L, raftery M, Rye KA, Stocker R. oxidation of methionine residues to methionine sulfoxides does not decrease potential antiatherogenic properties of apolipoprotein a-I. J Biol Chem. 2000;275: 19536-19544.
34. Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004;89: 4963-4971.
35. Eberini I, Calabresi L, Wait R, et al. Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein a-I at both the n-and C-termini. Biochem J. 2002;362: 627-634.
36. Eberini I, Gianazza E, Breghi L, et al. apolipoprotein a-I breakdown is induced by thrombolysis in coronary patients. Ann Med. 2007;39: 306-311.
37. Park KH, Jang WJ, Kim KY, Kim JR, Cho KH. Fructated apolipopro-tein a-I showed severe structural modifcation and loss of benefcial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. Biochem Biophys Res Commun. 2010; 392: 295-300.
38. Rye K, Hime NJ, Barter PJ. Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high-density lipoprotein size involve particle fusion. J Biol Chem. 1997;272: 3953-3960.
39. Liang H, Rye K, Barter PJ. Dissociation of lipid-free apolipoprotei-na-I from high-density lipoprotein. J Lipid Res. 1994;35: 1187-1199.
40. Clifton PM, Mackinnon AM, Barter PJ. Effects of serum amyloid a protein (Saa) on compositioN, size, and density of high density lipo-proteins in subjects with myocardial infarction. J Lipid Res. 1985;26: 1389-1398.
41. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and infammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45: 1169-1196.